Skip to Main Content

Paper Details

Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors.
Curr Cardiol Rep
3
2023
ABL, B cell malignancies, BCR, Bruton tyrosine kinase, Cardiovascular Toxicities, Epidermal growth factor, NSCLC, QT, Tyrosine, Tyrosine Kinase, Vascular endothelial, Vascular endothelial growth factor, advanced non-small cell lung cancer, arterial ischemic events, atrial and ventricular arrhythmias, breakpoint cluster region, breakpoint cluster region (BCR)-ABL TKIS, cancers, heart failure, hematologic or solid malignancies, hepatocellular carcinoma, hypertension, imatinib, patients, renal cell carcinoma, solid tumors, tumor, tyrosine, tyrosine kinase
Author NameAffiliation
Neeraj AgarwalHuntsman Cancer Institute, University of Utah
Jorge CortesMedical College of Georgia at Augusta University
Jorge CortesGeorgia Cancer Center, Medical College of Georgia, Augusta University
Neal L WeintraubMedical College of Georgia, Augusta University
Neal L WeintraubMedical College of Georgia, Augusta University
  • 1 - 5

Datasets

Release 1.2